University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Macular degeneration
Cure status
- 4D-150 IVT (3E10 vg/eye)Phase 3 · NCT07064759 · NCT06864988
- ABBV-RGX-314 Dose 1Phase 3 · NCT05407636 · NCT04514653
- ABBV-RGX-314 Dose 2Phase 3 · NCT05407636 · NCT04514653
- ABP 938 8 mgPhase 3 · NCT07614776
- AfliberceptPhase 3 · NCT07317934 · NCT07776522 · NCT06683742 · NCT07482176 · NCT07728981 · NCT06223958 · NCT06817343 · NCT06839339 · NCT06491914 · NCT06668064 · NCT06495918 · NCT07440225 · NCT06556368 · NCT07816315 · NCT06856577 · NCT07496567 · NCT07489586 · NCT07844148 · NCT07205887
- Aflibercept (EYLEA®)Phase 3 · NCT05407636
- Aflibercept (US) 8 mgPhase 3 · NCT07614776
- Aflibercept InjectionPhase 3 · NCT05769153 · NCT04101877 · NCT05251636
- Aflibercept OphthalmicPhase 3 · NCT05972473
- ALK-001Phase 3 · NCT07419334 · NCT04239625 · NCT02402660
- BevacizumabPhase 3 · NCT06952452 · NCT05112861
- CemdisiranPhase 3 · NCT06541704
- ElamipretidePhase 3 · NCT06373731
- Episcleral BrachytherapyPhase 3 · NCT05251636
- EYLEAPhase 3 · NCT06672536 · NCT07844148
- EYLEA® (aflibercept) Injection 2 mg (0.05mL)Phase 3 · NCT07064759 · NCT06864988 · NCT07557121
- Eylea® Solution for intravitreal injectionPhase 3 · NCT06470373
- EYP-1901Phase 3 · NCT06683742 · NCT06668064
- Faricimab Injection [Vabysmo]Phase 3 · NCT07461441
- IBI302Phase 3 · NCT05972473
- Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until month 12Phase 3 · NCT04663750
- Intravitreal 20% sulfahexafluoride (SF6) gas tamponadePhase 3 · NCT04663750
- Intravitreal injections of 6 mg faricimab on a Treat and Extend schedulePhase 3 · NCT05904028
- Ixo-vecPhase 3 · NCT07482176 · NCT07630649 · NCT06856577
- LX102Phase 3 · NCT07317934
- OCU410Phase 3 · NCT06018558 · NCT07770828
- OLN324Phase 3 · NCT07816315 · NCT07816289
- OTX-TKIPhase 3 · NCT07516132 · NCT06495918
- OTX-TKI (axitinib implant)Phase 3 · NCT06223958
- PDS Implant with Ranibizumab 100 mg/mLPhase 3 · NCT03683251
- PDS With Ranibizumab (100 mg/mL)Phase 3 · NCT05562947
- Port Delivery System with RanibizumabPhase 3 · NCT04657289
- PozelimabPhase 3 · NCT06541704 · NCT07230834
- QA108 granulesPhase 3 · NCT07189169
- QL1207H injectionPhase 3 · NCT07489586
- RanibizumabPhase 3 · NCT06847542 · NCT05562947 · NCT04657289 · NCT05210803 · NCT04514653 · NCT07816289
- Ranibizumab ControlPhase 3 · NCT07007065
- Ranibizumab Injection [Lucentis]Phase 3 · NCT05461339
- Ranibizumab OphthalmicPhase 3 · NCT06952452
- RBS-001 Solution for intravitreal injectionPhase 3 · NCT06470373
- SMZ1Phase 3 · NCT07695207
- subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mlsPhase 3 · NCT04663750
- Surabgene Lomparvovec (ABBV-RGX-314)Phase 3 · NCT07007065
- Susvimo PDS ImplantPhase 3 · NCT06847542
- TAB014 Monoclonal Antibody InjectionPhase 3 · NCT05461339
- Tabirafusp tedromerPhase 3 · NCT06556368
- Tarcocimab tedromerPhase 3 · NCT06556368
- TinlarebantPhase 3 · NCT05949593
- VonaprumentPhase 3 · NCT07807969 · NCT06510816
- ABBV-RGX-314Phase 2/3 · NCT04704921
- bispecific anti-VEGF and anti-complementPhase 2/3 · NCT07520318
- JNJ-81201887Phase 2/3 · NCT06635148
- Ranibizumab (LUCENTIS®)Phase 2/3 · NCT04704921
- TiespectusPhase 2/3 · NCT07440225 · NCT07496567
- ABBV-RGX-314 Dose 3Phase 2 · NCT04514653
- ABBV-RGX-314 Dose 4Phase 2 · NCT04514653
- ADVM-022Phase 2 · NCT05536973
- ADX-038Phase 2 · NCT06990269
- Aflibercept (Eylea)Phase 2 · NCT07798375
- Aflibercept intravitreal injectionPhase 2 · NCT06196840
- AIV007Phase 2 · NCT07557121
- AL-001Phase 2 · NCT06839339 · NCT06707753
- APL-3007, pegcetacoplan (APL-2)Phase 2 · NCT07215390
- Atorvastatin 80mgPhase 2 · NCT04735263
- Avacincaptad Pegol intravitreal solutionPhase 2 · NCT06659445
- Bevacizumab InjectionPhase 2 · NCT04101877
- BI 1584862Phase 2 · NCT06769048
- BI 771716Phase 2 · NCT06722157
- D-4517.2Phase 2 · NCT05387837
- DapagliflozinPhase 2 · NCT07174687
- Dimethyl Fumarate (TECFIDERA™)Phase 2 · NCT04292080
- Doxycycline HyclatePhase 2 · NCT04504123
- EG-301Phase 2 · NCT05170048
- FWY003Phase 2 · NCT07441642
- GAL-101Phase 2 · NCT06659549
- GT005Phase 2 · NCT05481827
- IBI302 8mg dosePhase 2 · NCT07275840
- JWK001Phase 2 · NCT07776522
- Local SteroidPhase 2 · NCT04514653
- Long term follow up in all patients who received SAR422459 in previous study TDU13583Phase 2 · NCT01736592
- LX102 subretinal injectionPhase 2 · NCT06198413 · NCT06196840
- NT-101 ophthalmic solutionPhase 2 · NCT07811726
- ONL1204 Opthalmic solutionPhase 2 · NCT06659445
- OpRegenPhase 2 · NCT05626114 · NCT02286089
- PegcetacoplanPhase 2 · NCT06722157
- PST-611Phase 2 · NCT07705568
- RemigromigPhase 2 · NCT07205887
- RGX-314Phase 2 · NCT03999801
- RO7965032Phase 2 · NCT07851259
- SCAI-005 0.04% 2drops TIDPhase 2 · NCT07607561
- SCAI-005 0.08% 2drops TIDPhase 2 · NCT07607561
- STL303Phase 2 · NCT07606365
- Surgical implantation of the CPCB-RPE1 implantPhase 2 · NCT06557460
- Topical SteroidPhase 2 · NCT04514653
- VIS-101 6.0mg High concentrationPhase 2 · NCT07798375
- VIS-101 6.0mg Low concentrationPhase 2 · NCT07798375
- VIS-101 9.0mg High concentrationPhase 2 · NCT07798375
- 4D-150 IVTPhase 1/2 · NCT05197270
- ABBV-6628Phase 1/2 · NCT07160179
- ABI-110 High DosePhase 1/2 · NCT06550011
- ABI-110 Low DosePhase 1/2 · NCT06550011
- ABI-110 Medium DosePhase 1/2 · NCT06550011
- ACDN-01Phase 1/2 · NCT06467344
- Aflibercept IVTPhase 1/2 · NCT05197270
- AR-14034 SR implantPhase 1/2 · NCT05769153
- AR-14034 SR implant higher dosePhase 1/2 · NCT05769153
- AR-14034 SR implant lower dosePhase 1/2 · NCT05769153
- BETA-TT8 ophthalmic gel 3.8% w/vPhase 1/2 · NCT07766473
- BRX011Phase 1/2 · NCT07029945
- BS01Phase 1/2 · NCT07158775
- CTx001Phase 1/2 · NCT07392255
- DiluentPhase 1/2 · NCT06660667
- EXG202 injectionPhase 1/2 · NCT07178249
- EYC-0305Phase 1/2 · NCT07587515
- Eyecyte-RPE™Phase 1/2 · NCT06394232
- FT-003Phase 1/2 · NCT06492863 · NCT05611424
- hiPSC-RPEsPhase 1/2 · NCT07418177
- HX9428 tabletPhase 1/2 · NCT07185841
- iPSC-derived RPE/PLGA transplantationPhase 1/2 · NCT04339764
- KH631Phase 1/2 · NCT05672121 · NCT05657301
- KH658Phase 1/2 · NCT06458595 · NCT06825858
- NG101 AAV gene therapyPhase 1/2 · NCT05984927
- PRL3-ZUMABPhase 1/2 · NCT07547228
- RPESC-RPE-4WPhase 1/2 · NCT04627428
- RRG001Phase 1/2 · NCT06141460
- SAR402663Phase 1/2 · NCT06660667
- SAR446597Phase 1/2 · NCT07215234
- SB-007Phase 1/2 · NCT06942572
- SCT520FFPhase 1/2 · NCT06672536
- SKG0106Phase 1/2 · NCT05986864
- SYFOVREPhase 1/2 · NCT07160179
- TO-O-1007 (high-dose)Phase 1/2 · NCT07668804
- TO-O-1007 (low-dose)Phase 1/2 · NCT07668804
- VOY-101Phase 1/2 · NCT06087458
- VV-14295Phase 1/2 · NCT06765980
- ABF-101Phase 1 · NCT07330674
- AcyclovirPhase 1 · NCT03178149
- Aflibercept Injection [Eylea]Phase 1 · NCT06132035
- ARO-033Phase 1 · NCT07662096
- ASP7317Phase 1 · NCT03178149
- Autologous iPSC-derived RPEPhase 1 · NCT05445063
- BBC1501Phase 1 · NCT05803785
- CD34+ bone marrow stem cells intravitrealPhase 1 · NCT01736059
- CG-P5 peptidePhase 1 · NCT06132035
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomesPhase 1 · NCT05147701
- GB10Phase 1 · NCT07406438
- GenSci148 InjectionPhase 1 · NCT07817615
- HG202Phase 1 · NCT06623279 · NCT06031727
- InjectionPhase 1 · NCT07594236
- IVB103 Injection（High dose）Phase 1 · NCT06737354
- IVB103 Injection（Intermediate dose）Phase 1 · NCT06737354
- IVB103 Injection（Low dose）Phase 1 · NCT06737354
- NystatinPhase 1 · NCT03178149
- OCU-10-C-110 for InjectionPhase 1 · NCT05904691
- Oral disulfiramPhase 1 · NCT06319872
- RetinoStatPhase 1 · NCT01678872
- tacrolimusPhase 1 · NCT03178149
- trimethoprim-sulfamethoxazolePhase 1 · NCT03178149
- AGX-08-HEarly phase 1 · NCT07602127
- AGX-08-LEarly phase 1 · NCT07602127
- EXG202Early phase 1 · NCT06888492
- Fluorescein sodium and Zeiss FF450 fundus cameraEarly phase 1 · NCT04008121
- FSN+Vitamin supplementEarly phase 1 · NCT07121127
- HG005Early phase 1 · NCT07063251
- LX111 InjectionEarly phase 1 · NCT07053358
- MB-102 and Zeiss FF450 fundus cameraEarly phase 1 · NCT04008121
- occupational therapy interventions for low vision careEarly phase 1 · NCT06593405
- Vitamin SupplementsEarly phase 1 · NCT07121127
- Whole Egg - 2Early phase 1 · NCT07021027
- Whole Egg - 4Early phase 1 · NCT07021027
Closest to patients
- A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular DegenerationPhase 3 trial: QL1207H injection, Aflibercept 8 mgQilu Pharmaceutical Co., Ltd. (sponsor)Phase 3Results expected 2026
- High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)Phase 3 trial: Macular degenerationClinique de Retine de L'Est · Montreal, CanadaPhase 3Results expected 2027
- QA108 Phase III Study in Subjects With Intermediate AMDPhase 3 trial: QA108 granulesSmilebiotek Zhuhai Limited (sponsor) · 1 hospital in ChinaPhase 3Results expected 2027
Choose one to continue
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Occurrence, progression and risk factors of macular atrophy in neovascular age-related macular degeneration according to neovascularization subtypes.
Occurrence, progression and risk factors of macular atrophy in neovascular age-related macular degeneration according to neovascularization subtypes.
Acta ophthalmologica
PubMed · PMID 42986005Review
Fluid fluctuation and visual outcomes in neovascular age-related macular degeneration: A systematic review and meta-analysis.
Fluid fluctuation and visual outcomes in neovascular age-related macular degeneration: A systematic review and meta-analysis.
Survey of ophthalmology
PubMed · PMID 42988275Publication
Central-field stimulus thresholds in age-related macular degeneration: Associations with visual function and retinal structure.
Central-field stimulus thresholds in age-related macular degeneration: Associations with visual function and retinal structure.
Advances in ophthalmology practice and research
PubMed · PMID 42991158
Organisations that can help
Helplines, patient groups and support services for you and your family.
Select your country to see the organisations there, starting with the ones closest to you.
Umbrella organisations (they connect national groups)
European Blind Union
European umbrella of national organisations of blind and partially sighted people; advocacy on accessibility, Marrakesh Treaty, braille, mobility; news, webinars, podcasts.
Visit site: European Blind Union
Retina International
Global umbrella of patient organisations for inherited and acquired retinal conditions (incl. retinitis pigmentosa, AMD); condition information, patient resources, research and advocacy.
Visit site: Retina International
World Blind Union
Global umbrella of organisations of blind and partially sighted people; advocacy on accessibility, Marrakesh Treaty, braille literacy, inclusive development; scholarships and awards.
Visit site: World Blind Union
General support
For anyone who is ill, whatever the disease: patients' rights and legal aid, crisis lines, hospice and palliative care, care in another EU country, and patient organisations' umbrella bodies.
International
European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)
International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' Organizations
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Macular degeneration work.
Singapore Eye Research Institute
Singapore, Singapore
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, Los Angeles
Los Angeles, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Singapore National Eye Center
Singapore, Singapore
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Doheny Eye Institute
Los Angeles, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
National University of Singapore
Singapore, Singapore
Team details appear once the team leader joins.
Is this your team? Claim it
University of Miami
Coral Gables, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Duke-NUS Medical School
Singapore, Singapore
Team details appear once the team leader joins.
Is this your team? Claim it